drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T cell therapy)
drug_description
Autologous genetically modified T-cell therapy expressing a chimeric antigen receptor targeting B7-H3 (CD276); antigen engagement activates T-cell cytotoxicity and cytokine release to kill B7-H3–positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intratumoral, Intracerebroventricular
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting B7-H3 (CD276). Upon binding B7-H3 on tumor cells, CAR signaling activates T-cell cytotoxicity and cytokine release, leading to selective killing of B7-H3–positive tumor cells.
drug_name
B7-H3 CAR-T
nct_id_drug_ref
NCT04077866